Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases businesswire.com Nawigacja wpisu U.S. Army Research Institute of Environmental Medicine’s GEMS program educates over 200 young students this summer – United States Army Pfizer launches direct sales website for common vaccines, medicines (NYSE:PFE) – Seeking Alpha
